MTOR and renal carcinoma: In renal carcinoma cell lines, HCQ enhanced the activity of mTOR inhibitors, such as everolimus, inhibiting mitochondrial oxygen consumption and promoting apoptosis through inhibition of S6 phosphorylation [44].